GOALS: We sought to determine the yield of stool analysis for bacterial culture, ova and parasites, and Clostridium difficile toxin in suspected relapses of inflammatory bowel disease (IBD). BACKGROUND: The diagnostic yield of such stool studies has not been examined recently in the United States. STUDY: The medical records of consecutive IBD patients who underwent stool testing for relapses at our institution between July 1, 2000, and November 25, 2001, were abstracted for demographics, stool test results, recent antibiotic exposure, and hospitalization. RESULTS: Fifty-four patients were evaluated during 62 relapses with 99 stool samples. Twelve stool tests were positive. C. difficile accounted for the majority of positive tests (10/12). Of these, 9 (90%) were associated with antibiotic use in the prior month versus 10 (22%) in the C. difficile-negative group (P < 0.001). Hospitalization, prednisone use, or sulfasalazine use did not differ significantly with C. difficile status. Eight C. difficile-positive patients improved clinically with targeted antibiotic therapy. Two bacterial cultures (4%) were positive for Campylobacter jejuni and Plesiomonas shigelloides. CONCLUSION: Stool studies yielded a pathogen, mainly C. difficile, in 20% of the relapsing IBD patients. Antibiotic use was significantly associated with a positive C. difficile toxin. Toxin-positive patients improved clinically with targeted antibiotics.
GOALS: We sought to determine the yield of stool analysis for bacterial culture, ova and parasites, and Clostridium difficile toxin in suspected relapses of inflammatory bowel disease (IBD). BACKGROUND: The diagnostic yield of such stool studies has not been examined recently in the United States. STUDY: The medical records of consecutive IBDpatients who underwent stool testing for relapses at our institution between July 1, 2000, and November 25, 2001, were abstracted for demographics, stool test results, recent antibiotic exposure, and hospitalization. RESULTS: Fifty-four patients were evaluated during 62 relapses with 99 stool samples. Twelve stool tests were positive. C. difficile accounted for the majority of positive tests (10/12). Of these, 9 (90%) were associated with antibiotic use in the prior month versus 10 (22%) in the C. difficile-negative group (P < 0.001). Hospitalization, prednisone use, or sulfasalazine use did not differ significantly with C. difficile status. Eight C. difficile-positive patients improved clinically with targeted antibiotic therapy. Two bacterial cultures (4%) were positive for Campylobacter jejuni and Plesiomonas shigelloides. CONCLUSION: Stool studies yielded a pathogen, mainly C. difficile, in 20% of the relapsing IBDpatients. Antibiotic use was significantly associated with a positive C. difficile toxin. Toxin-positive patients improved clinically with targeted antibiotics.
Authors: Francesca Turroni; Marco Ventura; Ludovica F Buttó; Sabrina Duranti; Paul W O'Toole; Mary O'Connell Motherway; Douwe van Sinderen Journal: Cell Mol Life Sci Date: 2013-03-21 Impact factor: 9.261
Authors: Ines Zollner-Schwetz; Kathrin A T Herzog; Gebhard Feierl; Eva Leitner; Georg Schneditz; Hanna Sprenger; Jürgen Prattes; Wolfgang Petritsch; Heimo Wenzl; Patrizia Kump; Gregor Gorkiewicz; Ellen Zechner; Christoph Högenauer Journal: Dig Dis Sci Date: 2015-06-20 Impact factor: 3.199
Authors: Ethan Mezoff; Elizabeth A Mann; Kim Ward Hart; Christopher J Lindsell; Mitchell B Cohen Journal: J Pediatr Gastroenterol Nutr Date: 2011-04 Impact factor: 2.839
Authors: Colleen R Kelly; Chioma Ihunnah; Monika Fischer; Alexander Khoruts; Christina Surawicz; Anita Afzali; Olga Aroniadis; Amy Barto; Thomas Borody; Andrea Giovanelli; Shelley Gordon; Michael Gluck; Elizabeth L Hohmann; Dina Kao; John Y Kao; Daniel P McQuillen; Mark Mellow; Kevin M Rank; Krishna Rao; Arnab Ray; Margot A Schwartz; Namita Singh; Neil Stollman; David L Suskind; Stephen M Vindigni; Ilan Youngster; Lawrence Brandt Journal: Am J Gastroenterol Date: 2014-06-03 Impact factor: 10.864
Authors: Dejan Micic; Andres Yarur; Alex Gonsalves; Vijaya L Rao; Susan Broadaway; Russell Cohen; Sushila Dalal; John N Gaetano; Laura R Glick; Ayal Hirsch; Joel Pekow; Atsushi Sakuraba; Seth T Walk; David T Rubin Journal: Dig Dis Sci Date: 2018-02-08 Impact factor: 3.199